The clinical technology company currently has global operations in over 100 countries and over 1000 sites, and its expanded Asia-Pacific presence will provide clinical operations and electronic consent (eConsent), electronic clinical outcome assessment (eCOA) solutions, interactive response technology, and other clinical management services.
The company closed its first full quarter in March 2019 and saw a 20% increase in new clinical trial business citing innovations to serve target patient populations as part of its success.
Mike Nolte, CEO of CRF Bracket, told us that the population of the region is far more than half of the world’s people and represents an under-served market that is genetically diverse.
This population enables the region to have a large and varied patient pool in an area with higher rates of disease and limited health care infrastructure. He said that all of these factors make both the research opportunity and potential impact of research on the communities ‘extraordinary.’
Nolte added that in the region, “Site infrastructure is growing, and new facilities tend to be first-rate with equipment able to produce high-quality data. There is also broad openness to technology as a critical accelerator for the conduct of research which provides fertile ground for innovation in software solutions.”
With the addition of the Tokyo office, the company’s trial technologies will be available to a large portion of the region, tapping into this fertile ground and bolstering research capabilities.
“Engaging individuals through technology, as an example, might overcome one significant barrier in the region, where there is low awareness of health care infrastructure broadly, much less, awareness of opportunities to participate in clinical research,” said Nolte.
CRF Bracket’s solutions have been used in to advance patient engagement and improve retention. The company recently launched TrialConsent, its eConsent solution, to optimize patient-centricity in trial participation by enabling participants to handle the time, place, and pace of consenting to a trial.
Additionally, its eCOA, TrialMax, was used in a Phase III prostate cancer study to enable the multi-site study to support the collection of patient-reported outcome (PRO) data. The study selected this type of solution as it provided patients flexibility in submitting PRO’s while still maintaining the integrity of the data.
“Extending the reach of limited infrastructure and overcoming complex and inconsistent regulatory environments are other areas where technology could play a significant role,” Nolte added.
